<DOC>
	<DOCNO>NCT00424229</DOCNO>
	<brief_summary>We evaluate incidence significant hematological response , accord IWG criterion include CR , PR , major HI , ( HI-E , Hl-N , Hl- P ) , cytogenetic response patient diagnose intermediate-2 high-risk ( International Prognostic Scoring System [ IPSS ] ) MDS deletion ( del ) 5q [ 31 ]</brief_summary>
	<brief_title>Lenalidomide Subjects With intermediate2 High MDS Associated With Deletion ( DEL ) 5q 31</brief_title>
	<detailed_description>Subjects meet inclusion exclusion criterion receive lenalidomide lenalidomide administer 10 mg ( two 5 mg capsule ) daily Days 1–21 , every 4 week . Bone marrow aspirate ( baseline course study week 8 , 16 , 32 , 52 clinically indicated/for assessment disease progression ) evaluation Subjects may participate study 52 week ( patient still respond 52 week , drug wil continue supply ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age &gt; 18 year time signing informed consent form MDS IPSS score Int2 high deletion 5q ( 31 ) Prior thalidomide allow Documented diagnosis MDS ( RA , RARS , RAEB , RAEBT CMML WBC &lt; 13,000/mm3 accord FAB classification ) meet IPSS criterion intermediate2 highrisk disease associate del 5q [ 31 ] ( delete chromosomal region must include 5q [ 31 ] ) , without additional cytogenetic abnormality Pregnant lactating female Prior therapy lenalidomide MDS IPSS score low Int1 Clinical neuropathy great grade 2 Proliferative ( WBC ≥ 13,000/mL ) chronic myelomonocytic leukemia ( CMML ) Recombinant human erythropoietin ( rHuEPO ) therapy receive within 28 day Use androgens treat hypogonadism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>MDS INT-2MDS HIGH RISKDELETION 5q [ 31 ] Lenalidomide</keyword>
</DOC>